Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Blood (2023) 142 (Supplement 1): 3164.

https://doi.org/10.1182/blood-2023-178790

Published: 2023

Journal Articles

Chronic Mitochondrial Dysfunction Renders Acute Myeloid Leukemia Resistant to Multipronged Inhibition of Mitochondrial Metabolism

Benjamin Bateman, Briana Bates, Michael Deininger, Helong Gary Gary Zhao

Blood (2023) 142 (Supplement 1): 2739.

https://doi.org/10.1182/blood-2023-179883

Published: 2023

Journal Articles

SIRT5 Regulates Energy Metabolism and Survival in Acute Lymphoblastic Leukemia Cells

Nataly Cruz-Rodriguez, Dongqing Yan, Briana Bates, Daniela Uribe-Cano, Tony Pomicter, Michael Deininger

Blood (2023) 142 (Supplement 1): 41.

https://doi.org/10.1182/blood-2023-174967

Published: 2023

Journal Articles

Addiction to Small Gtpase ARF6-Mediated Sphingolipid Homeostasis By AML but Not the Host

Helong Gary Gary Zhao, Kent Johnson, Tony Pomicter, Briana Bates, Benjamin Bateman, Jonathan Ahmann, Jenna Bishop, Dongqing Yan, Greg Lee, Torsten Haferlach, Weiquan Zhu, Shannon Odelberg, Michael Deininger

Blood (2023) 142 (Supplement 1): 1384.

https://doi.org/10.1182/blood-2023-174155

Published: 2023

Journal Articles

Always stressed but never exhausted: how stem cells in myeloid neoplasms avoid extinction in inflammatory conditions

Helong Gary Zhao, Michael Deininger

Blood (2023) 141 (23): 2797–2812.

https://doi.org/10.1182/blood.2022017152

Published: 2023

Journal Articles

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Blood (2022) 140 (Supplement 1): 205–207.

https://doi.org/10.1182/blood-2022-166452

Published: 2022

Journal Articles

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Blood (2021) 138 (21): 2042–2050.

https://doi.org/10.1182/blood.2021012082

Published: 2021

Includes: Supplemental data

Journal Articles

The effect of long-term ruxolitinib treatment on JAK2 p.V617F allele burden in patients with myelofibrosis

Michael Deininger, Jerald Radich, Timothy C. Burn, Reid Huber, Dilan Paranagama, Srdan Verstovsek

Blood (2015) 126 (13): 1551–1554.

https://doi.org/10.1182/blood-2015-03-635235

Published: 2015

Includes: Supplemental data

Journal Articles

Targeting Tyrosine Kinase Receptors

Michael Deininger, MD, PhD

Blood (2013) 122 (21): SCI-25.

https://doi.org/10.1182/blood.V122.21.SCI-25.SCI-25

Published: 2013

Journal Articles

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

Jerald P. Radich, Kenneth J. Kopecky, Frederick R. Appelbaum, Suzanne Kamel-Reid, Wendy Stock, Greg Malnassy, Elisabeth Paietta, Martha Wadleigh, Richard A. Larson, Peter Emanuel, Martin Tallman, Jeff Lipton, A. Robert Turner, Michael Deininger, Brian J. Druker

Blood (2012) 120 (19): 3898–3905.

https://doi.org/10.1182/blood-2012-02-410688

Published: 2012

Journal Articles

Zebrafish screen identifies novel compound with selective toxicity against leukemia

Blood (2012) 119 (24): 5621–5631.

https://doi.org/10.1182/blood-2011-12-398818

Published: 2012

Includes: Supplemental data

Journal Articles

Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years,

Blood (2011) 118 (21): 3766.

https://doi.org/10.1182/blood.V118.21.3766.3766

Published: 2011

Journal Articles

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

Jorge Cortes, MD, Moshe Talpaz, MD, Dale Bixby, Michael Deininger, MD, PhD, Neil Shah, MD, PhD, Ian W. Flinn, MD, PhD, Michael Mauro, MD, Thomas O'Hare, PhD, Simin Hu, PhD, Rebecca Kan, Victor M. Rivera, PhD, Tim Clackson, PhD, Frank Haluska, MD, PhD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 210.

https://doi.org/10.1182/blood.V116.21.210.210

Published: 2010

Journal Articles

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Michael Deininger, MD, PhD, Stephen G O'Brien, MD, PhD, François Guilhot, MD, John M Goldman, DM, FCRP, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, Jerald P. Radich, MD, Alan K. Hatfield, MD, FACP, Manisha Mone, PhD, Jeiry Filian, John Reynolds, Insa Gathmann, Richard A. Larson, MD, Brian J. Druker, MD

Blood (2009) 114 (22): 1126.

https://doi.org/10.1182/blood.V114.22.1126.1126

Published: 2009

Journal Articles

Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Hanna Jean Khoury, MD, Michael J. Mauro, MD, Yousif Matloub, MD, Tai-Tsang Chen, PhD, Erkut Bahceci, MD, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 1128.

https://doi.org/10.1182/blood.V114.22.1128.1128

Published: 2009

Journal Articles

Late Development of Cytogenetic Abnormalities in Ph Negative Cells of Chronic Myeloid Leukemia Patients Treated with Imatinib.

Michael Deininger, MD, PhD, François-Xavier Mahon, MD, Francois Guilhot, MD, Giuseppe Saglio, MD, Philipp le Coutre, MD, Arnon Nagler, MD, Anna D'Emilio, MD, Fabio Stagno, Enrica Morra, MD, Andrea Piccin, MD, Sarit E. Assouline, MD, Elisabetta Abruzzese, Valeria Santini, MD, Fabrizio Pane, MD, Pilar Giraldo, MD, Laura Antolini, PhD, Maria Grazia Valsecchi, PhD, Carlo Gambacorti-Passerini, MD

Blood (2009) 114 (22): 1108.

https://doi.org/10.1182/blood.V114.22.1108.1108

Published: 2009

Journal Articles

Defining Extrinsic Survival Pathways in CML Progenitor Cells.

Ryan Mackenzie, Jennifer Snead, PhD, Jonathan VanDyke, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 941.

https://doi.org/10.1182/blood.V114.22.941.941

Published: 2009

Journal Articles

The Oncogenic Role of Tumor Suppressor Protein p27 in Ph+ Chronic Myeloid Leukemia.

Anupriya Agarwal, PhD, Ryan Mackenzie, Dorian LaTocha, Kavin Vasudevan, Eduardo Firpo, Marc Loriaux, Keiichi Nakayama, Brian J. Druker, MD, James M Roberts, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 3276.

https://doi.org/10.1182/blood.V114.22.3276.3276

Published: 2009

Journal Articles

Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F.

Karl J. Aichberger, MD, PhD, Angela G. Fleischman, MD, PhD, Shirin Doratotaj, MD, Thomas G.P. Bumm, MD, Richard T. Silver, MD, Thomas G. Deloughery, MD, Heike L. Pahl, PhD, Brian J. Druker, MD, Christopher J. Burns, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 2917.

https://doi.org/10.1182/blood.V114.22.2917.2917

Published: 2009

Journal Articles

A Phase 1 Trial of Oral AP24534 in Patients with Refractory Chronic Myeloid Leukemia and Other Hematologic Malignancies: First Results of Safety and Clinical Activity against T315I and Resistant Mutations.

Jorge Cortes, MD, Moshe Talpaz, MD, Michael Deininger, MD, PhD, Neil Shah, MD, PhD, Ian W Flinn, MD, Michael J. Mauro, MD, Thomas O'Hare, PhD, Natalie Spinos, Simin Hu, PhD, Lori Berk, Narayana Narasimhan, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Frank Haluska, MD, PhD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 643.

https://doi.org/10.1182/blood.V114.22.643.643

Published: 2009

NARROW

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Chronic Mitochondrial Dysfunction Renders Acute Myeloid Leukemia Resistant to Multipronged Inhibition of Mitochondrial Metabolism

SIRT5 Regulates Energy Metabolism and Survival in Acute Lymphoblastic Leukemia Cells

Addiction to Small Gtpase ARF6-Mediated Sphingolipid Homeostasis By AML but Not the Host

Always stressed but never exhausted: how stem cells in myeloid neoplasms avoid extinction in inflammatory conditions

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

The effect of long-term ruxolitinib treatment on JAK2 p.V617F allele burden in patients with myelofibrosis

Targeting Tyrosine Kinase Receptors

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

Zebrafish screen identifies novel compound with selective toxicity against leukemia

Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years,

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Late Development of Cytogenetic Abnormalities in Ph Negative Cells of Chronic Myeloid Leukemia Patients Treated with Imatinib.

Defining Extrinsic Survival Pathways in CML Progenitor Cells.

The Oncogenic Role of Tumor Suppressor Protein p27 in Ph+ Chronic Myeloid Leukemia.

Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F.

A Phase 1 Trial of Oral AP24534 in Patients with Refractory Chronic Myeloid Leukemia and Other Hematologic Malignancies: First Results of Safety and Clinical Activity against T315I and Resistant Mutations.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only